Ultragenyx announced that the UK MHRA accepted its Marketing Authorisation Application for rebisufligene etisparvovec, a gene therapy for MPS IIIA. This marks a key regulatory milestone towards potential market authorization in the UK, following prior FDA approval and ongoing EMA review.
Ultragenyx announced the UK MHRA's acceptance of its Marketing Authorisation Application for rebisufligene etisparvovec, a gene therapy for MPS IIIA. This is a significant regulatory step, indicating the therapy is moving closer to potential approval and commercialization in the UK. This news is positive for Ultragenyx as it expands the potential market for their gene therapy, following FDA approval and ongoing EMA review. For traders, this represents a short-term positive catalyst, reinforcing the company's progress in bringing its therapy to market. The long-term implication is increased revenue potential if approved, but also continued regulatory hurdles and market access challenges.